Multiply Labs announces Series B to expand robotic biomanufacturing
Multiply Labs →On October 6, 2026, Multiply Labs announced a Series B financing led by Patrick Soon-Shiong with NantWorks. AstraZeneca, Lingotto, Teradyne and Strange Ventures joined as investors, while Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund participated. The company plans to further expand manufacturing capacity, advance product development and hire in engineering, regulatory and commercial functions. Its robotic clusters automate biologics manufacturing using customers' instruments and validated processes. Pharmaceutical manufacturers own and operate the systems. The expansion supports a transition from clinical deployments to commercial production, extending beyond cell and gene therapies into antibodies, viral vectors and mRNA.